The following primary antibodies were used in western blotting assays: NPM1 mutant (NB110-61646, Novus, Littleton, USA),
NPM1 WT (Thermo scientific, Rockford, USA), NPM1 (Sigma-Aldrich, St. Louis, USA), PBX3 (Abcam, Cambridge, USA),
HOXA9 (Abcam, Cambridge, USA),
Cleaved caspase 3,
Cleaved PARP (Cell Signaling, Danvers, USA),
Flag,
H3K4me2,
H3K9me2,
H3K27me2,
H3K36me2,
H3K79me1,
H3K79me2,
H3K79me3, H3,
DOT1L (Cell Signaling, Danvers, USA), and
β-Actin (Sigma, St. Louis, MO, USA).
All antibodies and the following kits applied in flow cytometry analyses were purchased from BD Biosciences (BD Pharmingen™, New Jersey, USA): CD45.1, CD45.2, Mac-1, Gr-1,
Sca-1,
c-Kit, Mouse Lineage Panel,
AnnexinV Apoptosis Detection kit, and BrdU Flow kit.
Immunofluorescence staining was performed with
Flag (Cell Signaling, Danvers, USA),
H3K79me2 (Cell Signaling, Danvers, USA and PMT-bio, Hangzhou, China), PBX3 (Santa Cruz, California, USA),
HOXA9 (Abcam, Cambridge, USA) and NPM1 antibodies as following: NPM1 mutant (Novus, Littleton, USA),
NPM1 WT (Thermo scientific, Rockford, USA), NPM1 (Cell Signaling, Danvers, USA).
Zhang W., Zhao C., Zhao J., Zhu Y., Weng X., Chen Q., Sun H., Mi J.Q., Li J., Zhu J., Chen Z., Pandolfi P.P., Chen S., Yan X, & Xu J. (2018). Inactivation of PBX3 and HOXA9 by down-regulating H3K79 methylation represses NPM1-mutated leukemic cell survival. Theranostics, 8(16), 4359-4371.